TSH receptor autoantibody immunoassay in patients with Graves' disease: Improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis

Tozzoli, Renato; Bagnasco, Marcello; Giavarina, Davide; Bizzaro, Nicola

doi:10.1016/j.autrev.2012.07.003

Cited by 166 publications

(119 citation statements)

References 50 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…However, this test does not differentiate the biological activity of the antibodies, TSAb and TBAb, which is possible using a bioassay based on cell culture and recombinant human TSHR, but is limited due to much efforts and costs. Secondgeneration TBII tests have 100% specificity and 98% diagnostic sensitivity [37][38][39].…”

Section: Thyrotropin Receptor Antibodies (Trab)mentioning

confidence: 99%

Rola układu immunologicznego oraz udział cytokin w patomechanizmie autoimmunologicznej choroby tarczycy (AITD)

Mikos¹,

Mikoś²,

Obara-Moszynska³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

Autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune disorder. AITD development occurs due to loss of immune tolerance and reactivity to thyroid autoantigens: thyroid peroxidase (TPO), thyroglobulin (TG) and thyroid stimulating hormone receptor (TSHR). This leads to infiltration of the gland by T cells and B cells that produce antibodies specific for clinical manifestations of hyperthyroidism in Graves' disease (GD) and chronic autoimmune thyroiditis (cAIT). In addition, T cells in Hashimoto's thyroiditis induce apoptosis in thyroid follicular cells, leading ultimately to the destruction of the gland. Cytokines are involved in the pathogenesis of thyroid diseases working in both the immune system and directly targeting the thyroid follicular cells. They are involved in the induction and effector phase of the immune response and inflammation, playing a key role in the pathogenesis of autoimmune thyroid disease. The presence of multiple cytokines has been demonstrated: IL-1a, IL-1b, IL-2, IL-4 , IL-6, IL-8, IL-10, IL-12, IL-13, IL-14, TNF-a and IFN-g within the inflammatory cells and thyroid follicular cells. Finally, cytokines derived from T cells can directly damage thyroid cells, leading to functional disorders and may also stimulate the production of nitric oxide (NO) and prostaglandin (PG), thus increasing the inflammatory response in AITD. Immunological mechanisms involved in the pathogenesis of AITD are strongly related to each other, but differences in the image of cAIT and GD phenotype are possibly due to a different type of immune response observed in these two counteracting clinical thyroid diseases. This article describes the potential role of cytokines and immune mechanisms in the pathogenesis of AITD. (Endokrynol Pol 2014; 65 (2): 150-155)

show abstract

Section: Thyrotropin Receptor Antibodies (Trab)mentioning

confidence: 99%

Rola układu immunologicznego oraz udział cytokin w patomechanizmie autoimmunologicznej choroby tarczycy (AITD)

Mikos¹,

Mikoś²,

Obara-Moszynska³

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…8,15,16 Thyroid receptor antibodies, otherwise known as thyroid binding immunoglobulins (TBII), have a specificity of 99% and sensitivity of 97% for diagnosing GD. 13 Thyroid Peroxidase antibodies (anti-TPO) are almost always positive in SPT and up to 70% of GD; therefore they are not useful to make a distinction between the two conditions.…”

Section: Differences Between Gd and Spt As A Cause Of Thyrotoxicosismentioning

confidence: 99%

“…13 Thyroid Peroxidase antibodies (anti-TPO) are almost always positive in SPT and up to 70% of GD; therefore they are not useful to make a distinction between the two conditions. 8,15 Hypothyroidism Symptoms and signs for hypothyroidism are less specific and overlap with those of many other medical conditions, including MS. Common symptoms of hypothyroidism include, dry skin, cold sensitivity, fatigue, muscle cramps, voice change, and constipation. Severe hypothyroidism can also present with carpal tunnel syndrome and sleep apnea.…”

Section: Differences Between Gd and Spt As A Cause Of Thyrotoxicosismentioning

confidence: 99%

Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

Mahzari

Arnaout

Freedman

2015

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Alemtuzumab, an anti-CD52 monoclonal antibody, was recently approved for treatment of MS in Canada, having shown to significantly reduce relapses and disability in patients, particularly those who relapsed despite first line treatment. Offsetting its benefit however, is the development of novel secondary autoimmune disease, particularly affecting the thyroid gland in up to 36% of patients. The incidence of Alemtuzumab induced thyroid dysfunction (AITD) will likely rise as alemtuzumab becomes more widely used for treating MS. We review the clinical and investigational cues that help delineate the aetiology and management of thyrotoxicosis and hypothyroidism in ATID. AITD can be easily managed and we present a simple approach for its evaluation and management by neurologists that should be implemented prior to considering a referral to an internist or endocrinologist for further opinion or treatment.RÉSUMÉ: Maladie thyroïdienne induite par l'alemtuzumab dans la sclérose en plaques: revue et traitement. L'alemtuzumab, un anticorps monoclonal dirigé contre CD52, a récemment été approuvé pour le traitement de la sclérose en plaques (SP) au Canada. Les études ont démontré qu'il diminuait significativement les rechutes et l'invalidité chez les patients, particulièrement chez ceux qui avaient eu des rechutes malgré le traitement de première intention. Cependant, l'apparition d'une nouvelle maladie auto-immune secondaire à ce traitement, touchant la glande tyroïde chez 36% des patients, en amoindrit les bénéfices. L'incidence de la dysfonction thyroïdienne induite par l'alemtuzumab (DTIA) augmentera vraisemblablement à mesure que l'alemtuzumab sera plus fréquemment prescrit pour traiter la SP. Nous revoyons les indices cliniques et biochimiques qui aident à définir l'étiologie et le traitement de la thyrotoxicose et de l'hypothyroïdie dans la DTIA. La DTIA peut être traitée facilement et nous présentons une approche simple de son évaluation et son traitement par des neurologues. Cette approche devrait être utilisée avant d'envisager de référer le patient à un interniste ou à un endocrinologue pour connaître son opinion ou pour prescrire un traitement.

show abstract

“…However, third-generation TRAb assays, which use the monoclonal thyroid-stimulating antibody M22 labeled either with biotin in ELISAs or with ruthenium in the automated Elecsys®/Cobas®, have also been developed. It is now established that these third-generation assays have no clinical advantages over second-generation methods in the diagnosis (2,3 ) or in the follow-up of Graves disease patients (4 ). Recently, it has been reported that the automated third-generation TRAb assays should be performed on clinical chemistry platforms and should prompt appropriate revision of the current thyroid guidelines (2 ).…”

mentioning

confidence: 99%

“…It is now established that these third-generation assays have no clinical advantages over second-generation methods in the diagnosis (2,3 ) or in the follow-up of Graves disease patients (4 ). Recently, it has been reported that the automated third-generation TRAb assays should be performed on clinical chemistry platforms and should prompt appropriate revision of the current thyroid guidelines (2 ). The scientific community should be aware of the consequences of such a decision.…”

mentioning

confidence: 99%

Thyroid-Stimulating Hormone Receptor Antibody Assays: Recommendation for Correct Interpretation of Results in Graves Disease

Massart

d’Herbomez

2013

Clinical Chemistry

View full text Add to dashboard Cite

TSH receptor autoantibody immunoassay in patients with Graves' disease: Improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis

Cited by 166 publications

References 50 publications

Rola układu immunologicznego oraz udział cytokin w patomechanizmie autoimmunologicznej choroby tarczycy (AITD)

Rola układu immunologicznego oraz udział cytokin w patomechanizmie autoimmunologicznej choroby tarczycy (AITD)

Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

Thyroid-Stimulating Hormone Receptor Antibody Assays: Recommendation for Correct Interpretation of Results in Graves Disease

Contact Info

Product

Resources

About